Student Edition   Industry Edition  
 
TCS enters into drug discovery deal

Tata Consultancy Services (TCS), a leading global technology services company, has entered into an agreement with an Italian biotech firm Congenia, to provide advanced fragment-based lead optimization solutions for drug discovery.

The research division of TCS life sciences department will work on "P66" identified by Congenia as a key protein involved in several age-related diseases and will develop optimized drug leads based on this.

TCS will use modules of its product "Bio-Suite" to work on the target protein. It will screen a "virtual fragment library" of tens of thousands of potential lead molecules to predict which of these might bind themselves to the target protein and thereby inhibit its function.

The work will be executed in the Advanced Technology Centre of TCS in Hyderabad , where the bulk of research and development work related to life sciences is done.

The agreement with the biotechnology start-up promoted by Italy 's Genextra SpA group is claimed to be the first of its kind for an IT company.


© Amity Edumedia. All Rights Reserved.
Powered By AKC Data Systems (India) Pvt. Ltd.
Private Policy | Disclaimer